[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Observation
January 2015

Intralesional Rituximab for Primary Iris Lymphoma

Author Affiliations
  • 1Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan, Ann Arbor
JAMA Ophthalmol. 2015;133(1):104-105. doi:10.1001/jamaophthalmol.2014.3303

Primary B-cell mucosa-associated lymphoid tissue (MALT) lymphoma of the iris is rare. The largest published series of 14 iris lymphomas included 3 such lymphomas.1 Thus, data concerning the effectiveness of treatment of these tumors are limited. External radiotherapy (the main treatment), resection, and systemic chemotherapy can cause substantial morbidity. Rituximab monoclonal antibody, targeting CD20 on B cells, has been used systemically and intralesionally to treat orbital and primary intraocular lymphomas and ocular inflammatory diseases.2,3 To our knowledge, we report the first case of primary iris MALT lymphoma treated with intralesional rituximab injection.

First Page Preview View Large
First page PDF preview
First page PDF preview
×